SEC Tracker
Get the app
SMMT · XBRL financial data

Summit Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SMMT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*——00*——————
Research and development1525*31———51208——133158
General and administrative512*12142014*1636010378*6363
Total operating expenses2136*43605866*67568234225*195220
Other operating income (expense)00*00(0)0*——————
Operating income (loss)(20)(36)*(42)(60)(58)(66)*——————
Interest expense33*3320*0000*——
Other income (expense)(0)(0)*0000*—(0)00*—1
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(21)(37)*(43)(60)(56)(61)*(63)(566)(232)(219)*(189)(216)
Earnings per share, basic USD per share(0.03)—(0.06)(0.09)(0.08)(0.08)*(0.09)(0.76)(0.31)(0.29)*(0.24)(0.28)
Earnings per share, diluted USD per share(0.03)—(0.06)(0.09)(0.08)(0.08)*(0.09)(0.76)(0.31)(0.29)*(0.24)(0.28)
Weighted average shares, basic millions of shares698701*702708727738*738743743766*775778
Weighted average shares, diluted millions of shares698701*702708727738*738743743766*775778

Balance sheet

CSV

Fiscal quarters (SMMT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2471612894105212298239225107419
Short-term investments1751159529739330715000488492271
Accounts receivable00——————————
Prepaid and other current assets—352211911871830
Total current assets205190163329490424371309246720617721
Property and equipment, net000000111122
Right-of-use asset669987665211919
Goodwill222222222222
Total assets218203177342503436384324262751648752
Accounts payable33633552322202823
Accrued liabilities497121820212627324465
Total current liabilities114202314059423560657383104
Lease liability, non-current436543323181717
Total liabilities119125133147654739656992102122
Accumulated deficit(957)(993)(1,037)(1,097)(1,153)(1,215)(1,277)(1,843)(2,075)(2,294)(2,484)(2,699)
Total stockholders' equity997844195438389344259192659546630
Total liabilities and equity218203177342503436384324262751648752
Common shares outstanding (cover page) millions of shares701702702725737738743743744775776798

Cash flows

CSV

Fiscal quarters (SMMT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(21)(37)*(43)(60)(56)(61)*(63)(566)(232)(219)*(189)(216)
Stock-based compensation1*9*1011*19*11*11479*131*112*7369*
Net cash from operating activities(15)*(19)*(30)(33)*(30)*(49)*(61)(67)*(93)*(102)*(122)(141)*
Purchases of property and equipment0*0*00*0*0*00*0*0*01*
Net cash from investing activities(3)*61*20(200)*(109)*83*160151*(0)*(485)*(0)223*
Proceeds from issuing common stock0*0*00*————————
Net cash from financing activities0*6*0200*204*(24)*82*34*574*4231*
Net change in cash(18)*48*(10)(33)*65*11*10786*(59)*(13)*(119)313*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Summit Therapeutics419not reported(141)*797.7M4.9 quarters 10-QJun 30, 2026
Cytokinetics25529(160)*139.0M7.3 quarters 10-QJun 30, 2026
TG Therapeutics48324039*153.1M— 10-QJun 30, 2026
Catalyst Pharmaceuticals75614960122.4M— 10-QMar 31, 2026
Xenon Pharmaceuticals120not reported(95)*96.8M9.8 quarters 10-QJun 30, 2026
Twist Bioscience117not reported1.1*62.7M— 10-QJun 30, 2026
Acadia Pharmaceuticals385308101*172.3M— 10-QJun 30, 2026
Protagonist Therapeutics420213219*64.7M— 10-QJun 30, 2026
Vericel1257716*51.2M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.